文献速递消化道肿瘤与早癌

ATBC研究中血清胃饥饿素与结直肠腺癌风险相关

Serum ghrelin is associated with risk of colorectal adenocarcinomas in the ATBC study.
PubMed 文献 · Gut · 2017-08-16

在芬兰男性吸烟者的ATBC队列中嵌套病例对照研究,分析284例结肠癌、239例直肠癌和523例对照,发现低血清胃饥饿素与结直肠癌风险升高相关(Q1 vs Q4:OR 1.57,95%CI 1.05–2.34);采血后10年内发病者风险更高(OR 10.86),20年后发病者风险降低(OR 0.26)。

要点

  • 低血清胃饥饿素与结直肠癌风险升高相关(Q1 vs Q4:OR 1.57,95%CI 1.05–2.34)。
  • 采血后10年内发病者,最低四分位胃饥饿素者风险更高(OR 10.86,95%CI 5.01–23.55)。
  • 采血后20年以上发病者,低胃饥饿素与风险降低相关(OR 0.26,95%CI 0.11–0.64)。

核心结论

  • 低血清胃饥饿素与采血后10年内结直肠癌风险升高相关,而与20年后发病风险降低相关。
  • 作者认为胃饥饿素浓度可能在癌变过程中变化。

研究设计与样本

  • 在芬兰男性吸烟者(50–69岁)的Alpha-Tocopherol, Beta-Carotene Cancer Prevention(ATBC)研究队列中嵌套的病例对照研究。
  • 纳入284例结肠癌、239例直肠癌和523例对照,按年龄、采血日期和血清可用性匹配。
  • 采用多变量条件logistic回归计算OR和95%CI。

主要发现

  • 总体低血清胃饥饿素与结直肠癌风险升高显著相关(Q1 vs Q4:OR 1.57,95%CI 1.05–2.34)。
  • 采血后10年内发病者,最低四分位胃饥饿素者比更高水平者更可能发生结直肠癌(OR 10.86,95%CI 5.01–23.55)。
  • 采血后20年以上发病者,低血清胃饥饿素者相对最高四分位者结直肠癌风险降低(OR 0.26,95%CI 0.11–0.64)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Colorectal cancers are the third most common cancers in women and men in the USA. While dietary and lifestyle factors such as Western diet, physical inactivity and obesity have been linked to an increased risk of this malignancy, the mechanisms for these associations are unclear. GI hormones, including ghrelin, are involved in energy balance by mediating appetite and metabolism; however, the association between ghrelin and colorectal cancer has not been studied. METHODS: We conducted a case-control study nested within the all-male Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study of Finnish smokers (aged 50-69 years) to examine serum ghrelin concentration and colorectal cancer risk. Data from 284 colon and 239 rectal cancers and 523 controls (matched on age, date of blood draw and serum availability) were analysed. ORs and 95% CIs were calculated using multivariable (conditional) logistic regression. RESULTS: Overall, low-serum ghrelin was significantly associated with increased risk of colorectal cancer (Q1 vs Q4: OR:1.57, 95% CI 1.05 to 2.34). For individuals developing tumours within 10 years of blood draw, those in the lowest quartile of serum ghrelin concentrations were statistically significantly more likely to develop colorectal cancers than those with higher serum ghrelin concentrations (OR: 10.86, 95% CI 5.01 to 23.55). However, for individuals with tumours developing more than 20 years after blood draw, low-serum ghrelin concentrations were associated with a decreased risk of colorectal cancer relative to those with the highest serum ghrelin concentrations (OR: 0.26, 95% CI 0.11 to 0.64). CONCLUSION: Low-serum ghrelin was associated with an increased colorectal cancer risk within 10 years of blood draw with a decreased risk for developing colorectal cancer more than 20 years after blood draw. These results suggest that ghrelin concentrations may vary across the carcinogenic process.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Murphy G, Cross AJ, Dawsey SM, et al. Serum ghrelin is associated with risk of colorectal adenocarcinomas in the ATBC study. Gut. 2017. PMID: 28814486. doi:10.1136/gutjnl-2016-313157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。